All In Biotech

Drug Trial Radar · NCT03866993

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Dec 20, 2018

Primary completion

Oct 8, 2020

Study completion Jan 14, 2022

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
Collaborators
Akeso Tiancheng, Inc
First posted
Mar 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, randomized, double-blinded, multicenter clinical study to evaluate the efficiency and safety of AK105 (Anti-PD1 antibody) plus paclitaxel and carboplatin vs placebo plus paclitaxel and carboplatin as First-line Therapy in patients with metastatic squamous non-small cell lung cancer.

Conditions

  • Lung Cancer Non-small Cell Stage IV
  • Squamous Cell Lung Cancer

Interventions

  • AK105Biological

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • PlaceboDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1Time frame: Up to approximately 2 years
  2. PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1Time frame: Up to approximately 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.